slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,387
Current window 10,801-10,830
Pages 3,680
Rows per page 30
Component
10,801-10,830 of 110,387
27
The chart uses a 7-point Likert scale. The top 4 categories are highlighted in green.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
28
The slide uses a list format with icons to categorize qualitative feedback from interviews.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
30
The slide uses a structured table to map trends to operational/technical complexity and their specific implications.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
31
The slide uses a chronological framework to explain the shift from paper-based to integrated digital platforms in clinical trials.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
32
The chart combines a horizontal bar chart for penetration rates with a stakeholder usage matrix.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
33
Includes bilingual survey methodology notes.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
34
The slide uses a combination of quantitative survey data and qualitative expert quotes to validate the trend towards smart clinical trial formats.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
35
The slide tracks the progression of Chinese regulatory guidelines (CDE) towards patient-centric and remote clinical trial methodologies.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
36
The slide uses a split-layout to contrast positive drivers against negative barriers.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
37
The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
39
The slide uses a circular flow diagram to represent a reciprocal relationship between two market actors.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
40
Survey data from IQVIA/L.E.K. Consulting (N=56).Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
42
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
43
The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
44
The slide highlights the trend of international pharma companies licensing innovative assets from Chinese biotech firms.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
45
The slide highlights a strategic shift in MNC R&D presence in China, moving towards collaborative incubation models.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
46
The slide uses a stacked bar chart to represent survey data (N=81) and includes two testimonial quotes from R&D leads.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
50
The slide presents qualitative interview profiles and quantitative survey respondent demographics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
58
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
02
The slide uses a structured table format to map market drivers to their specific impacts.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
03
The chart is a waterfall representation of survey responses regarding future IT outsourcing spend.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
04
The chart uses a stacked bar format to illustrate market growth across three segments: ITO, BPO, and Application development.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
05
The chart shows a bridge from 100 to 92, with a +5 increase and a -13 decrease.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
06
The slide highlights a shift in spending towards specialized IT services.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
07
The slide uses a 100% stacked bar chart to show the shift in revenue mix and its impact on operating profit.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
02
The slide uses a maturity model/spectrum framework to show the evolution of surgical technology.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
03
The slide uses a structured list format to contrast patient and surgeon benefits.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
04
The slide highlights 'Soft tissue surgical robots' as the focus of the report using a dashed orange box.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
05
The chart uses bubble size to represent the number of global surgical procedures and position on the curve to represent penetration level.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
06
The slide uses a bar chart to visualize market growth and a callout box to highlight the projected market value.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit